Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Brian Jonas, Sangeetha Venugopal, George Yaghmour, Manu Pandey, Anthony Selwyn Stein, Mikkael Sekeres, Namrata Chandhok, Rasmus Hoeg, Joseph Tuscano, Pamela Becker, Terrence Bradley, Eric Tam, Guido Marcucci, Paul Frankel, Jan Beumer, Steven Gore, Alexey Danilov, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2025-1651

Published: 2025

Journal Articles

Selective targeting of sumoylation disrupts mitochondrial homeostasis via TRAP1 to suppress growth of non-Hodgkin lymphoma (NHL) B-cells

Vi Lam, Tingting Liu, Haifeng Shen, Olga Danilova, Katarzyna Dabrowska, Sonia Rodriguez-Rodriguez, Courtney Jones, Martina Cusan, Angelo D'Alessandro, Lapo Alinari, Lili Wang, Tycel Phillips, Patrick Pirrotte, Zheng Xia, Alexey Danilov

Blood (2025) 146 (Supplement 1): 5087.

https://doi.org/10.1182/blood-2025-5087

Published: 2025

Journal Articles

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial

Blood (2025) 146 (Supplement 1): 86.

https://doi.org/10.1182/blood-2025-86

Published: 2025

Journal Articles

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Blood (2025) 146 (Supplement 1): 5521.

https://doi.org/10.1182/blood-2025-5521

Published: 2025

Journal Articles

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study

Blood (2025) 146 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2025-5384

Published: 2025

Journal Articles

Prior bendamustine exposure does not compromise clinical outcomes of bispecific antibody therapy in patients with relapsed/refractory non-Hodgkin lymphoma: A cubic consortium analysis

Blood (2025) 146 (Supplement 1): 6294.

https://doi.org/10.1182/blood-2025-6294

Published: 2025

Journal Articles

A phase 2 study with tafasitamab and zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma – taza CLL

Georgios Pongas, Matthew Mei, Lu Chen, Geoffrey Shouse, Rachel Bellsmith, Ivana Melgar, Steven Rosen, Tanya Siddiqi, Alexey Danilov

Blood (2025) 146 (Supplement 1): 2134.

https://doi.org/10.1182/blood-2025-2134

Published: 2025

Journal Articles

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Tycel Phillips, Lu Chen, Tiffanie Barnhizer, Alex Herrera, Geoffrey Shouse, Daniel Ermann, Reem Karmali, Adam Kittai, Manali Kamdar, Diane Smith, James Godfrey, Brian Sworder, Swetha Thiruvengadam, John Baird, Avyakta Kallam, Elizabeth Budde, Alexey Danilov

Blood (2025) 146 (Supplement 1): 883.

https://doi.org/10.1182/blood-2025-883

Published: 2025

Journal Articles

MGA loss promotes mitochondrial structure changes and redox adaptation in richter's transformation

Prajish Iyer, Girish Venkataraman, Joo Song, Oliche Brown, Dalmas Odhiambo, Wing Chan, Tanya Siddiqi, Steven Rosen, Alexey Danilov, Lili Wang

Blood (2025) 146 (Supplement 1): 5655.

https://doi.org/10.1182/blood-2025-5655

Published: 2025

Journal Articles

Pirtobrutinib, a non-covalent BTK inhibitor, enhances T-cell anti-tumor immunity in chronic lymphocytic leukemia (CLL)

Sonia Rodriguez-Rodriguez, Tiana Huynh, Vi Lam, Keika Yan, Andrew Chen, Tanya Siddiqi, Alexey Danilov

Blood (2025) 146 (Supplement 1): 3878.

https://doi.org/10.1182/blood-2025-3878

Published: 2025

Journal Articles

Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial

Philip Thompson, Tamar Tadmor, Hans Herluf Bentzen, Raul Cordoba, Sylvia Snauwaert, Neta Goldschmidt, Martin Simkovic, Jacob Christensen, Javier Lopez Jimenez, Ohad Benjamini, Toshihiko Oki, Andrew J. Steele, Marie Holst Mørch, Ernestine Tucker, Rebecca Valentin, Alexey Danilov, Umberto Vitolo

Blood (2025) 146 (Supplement 1): 1015.

https://doi.org/10.1182/blood-2025-1015

Published: 2025

Journal Articles

Trial in progress - a randomized study of ASTX727 with or without Iadademstat in accelerated/blast-phase myeloproliferative neoplasms

Anand Patel, Michael Drazer, Theodore Karrison, Lorraine Pelosof, Steven Gore, Richard Little, Alexey Danilov, Olatoyosi Odenike

Blood (2025) 146 (Supplement 1): 3827.

https://doi.org/10.1182/blood-2025-3827

Published: 2025

Journal Articles

Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment naïve follicular lymphoma

Blood (2025) 146 (Supplement 1): 5373.

https://doi.org/10.1182/blood-2025-5373

Published: 2025

Journal Articles

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 798.

https://doi.org/10.1182/blood-2025-798

Published: 2025

Journal Articles

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

Blood (2025) 146 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2025-6364

Published: 2025

Journal Articles

The efficacy and safety of pirtobrutinib in patients with CLL/SLL: A phase 2 dose optimization trial in progress

Alexey Danilov, Alvaro Alencar, Jackson Gao, Jennifer Chen Zhao, Minna Balbas, Vishalkumar Patel, Suhyun Kang, Bruce Cheson

Blood (2025) 146 (Supplement 1): 5690.

https://doi.org/10.1182/blood-2025-5690

Published: 2025

Journal Articles

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

Blood (2025) 146 (Supplement 1): 5351.

https://doi.org/10.1182/blood-2025-5351

Published: 2025

Journal Articles

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1742.1.

https://doi.org/10.1182/blood-2024-198727

Published: 2024

Journal Articles

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Jennifer E. Amengual, Hongli Li, Patrick M. Reagan, Tareq Al Baghdadi, Hayder Saeed, Joseph M Unger, Alexey Danilov, Michael Leblanc, Jonathan W. Friedberg, Sonali M. Smith

Blood (2024) 144 (Supplement 1): 3123.2.

https://doi.org/10.1182/blood-2024-199784

Published: 2024

Journal Articles

Integrating Metabolomics and Molecular Pathways to Uncover Therapeutic Vulnerabilities in Richter's Transformation

Prajish Iyer, Brian Jiang, Girish Venkataraman, Joo Y. Song, Wing Chung Chan, Tanya Siddiqi, Steven T. Rosen, Alexey Danilov, Antje Gohla, Lili Wang

Blood (2024) 144 (Supplement 1): 760.

https://doi.org/10.1182/blood-2024-199843

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Selective targeting of sumoylation disrupts mitochondrial homeostasis via TRAP1 to suppress growth of non-Hodgkin lymphoma (NHL) B-cells

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study

Prior bendamustine exposure does not compromise clinical outcomes of bispecific antibody therapy in patients with relapsed/refractory non-Hodgkin lymphoma: A cubic consortium analysis

A phase 2 study with tafasitamab and zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma – taza CLL

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

MGA loss promotes mitochondrial structure changes and redox adaptation in richter's transformation

Pirtobrutinib, a non-covalent BTK inhibitor, enhances T-cell anti-tumor immunity in chronic lymphocytic leukemia (CLL)

Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial

Trial in progress - a randomized study of ASTX727 with or without Iadademstat in accelerated/blast-phase myeloproliferative neoplasms

Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment naïve follicular lymphoma

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

The efficacy and safety of pirtobrutinib in patients with CLL/SLL: A phase 2 dose optimization trial in progress

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Integrating Metabolomics and Molecular Pathways to Uncover Therapeutic Vulnerabilities in Richter's Transformation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only